Intralesional SD-101 in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naïve Head and Neck Squamous Cell Carcinoma: Results from a Multicenter, Phase II Trial.

Intralesional SD-101 in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naïve Head and Neck Squamous Cell Carcinoma: Results from a Multicenter, Phase II Trial. Clin Cancer Res. 2022 03 15; 28(6):1157-1166.

View in: PubMed

subject areas

Antibodies, Monoclonal, Humanized
B7-H1 Antigen
Head and Neck Neoplasms
Humans
Papillomavirus Infections

authors with profiles

Ezra Cohen